squalamine

squalamine

(skwā′lĭ-mēn″) [L. squalus, dogfish + ″]
An antiangiogenic protein, originally isolated from dog sharks. It has been used to treat the neovascularization of age-related macular degeneration and to limit blood vessel proliferation needed by a cancer for it to spread and survive.

squalamine

A drug extracted from the dogfish that has been claimed to be capable of killing a range of sexually-transmitted bacteria including the gonococcus and Chlamydia and of killing cells invaded by viruses.
Mentioned in ?
References in periodicals archive ?
Results from the phase II IMPACT study of squalamine lactate, based on an extract from the tissues of dogfish sharks, continue to show promise for AMD patients.
2% Squalamine lactate ophthalmic solution) combination therapy for the treatment of the wet form of age-related macular degeneration (wet-AMD).
Zasloff discovered the molecule, squalamine, in 1993 in the dogfish shark, a small-to medium-size shark found in the Atlantic, Pacific, and Indian Oceans.
Squalamine, a cholesterollike molecule, is thought to be a key element of the shark's primitive immune system.
The compound, squalamine, has been in human clinical trials for the treatment of cancer and several eye disorders, and so has a well-known safety profile, suggesting it can be quickly tested as a new class of drugs to treat infections caused by these viruses.
Genaera's other programs include: squalamine for the treatment of cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; LOMUCIN, a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease; and trodusquemine (MSI-1436) for the treatment of obesity.
These include squalamine, an anti-angiogenesis treatment for eye disease and cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN(TM), a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease.
Called squalamine, this steroid resembles plant compounds now used to kill intestinal parasites.
Aided awareness among physicians is highest for products in development for wet AMD, primarily Ohr Pharmaceutical's Squalamine (45 percent), followed by Ophthotech's Fovista (39 percent) and GlaxoSmithKline's pazopanib (29 percent).
However, the anti-VEGF monopoly is set to take a dramatic tumble due to the launch of novel adjunctive therapies for wet AMD, Fovista and squalamine, and the introduction of two therapies for dry AMD, lampalizumab and emixustat, during the forecast period.
Drivers of emerging wet AMD therapy value : Among emerging wet AMD therapies surveyed, the greatest percentage of EU5 retinal specialists perceived Novartis's Fovista and Ohr Pharmaceuticals' squalamine as offering the greatest value to their treatment of wet AMD.
These include squalamine, an anti-angiogenesis treatment for eye disease and cancer; interleukin-9 antibody, a respiratory treatment based on the discovery of a genetic cause of asthma; and LOMUCIN, a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease.